Preventing infections with antibiotics or immunoglobulin in blood disorders
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be on IVIg (intravenous immunoglobulin) replacement at a standard dose to prevent bacterial infections for at least 6 months straight.
- You and your doctor agree that stopping IVIg is not a safe option for you right now.
- You have not had a stem cell transplant from a donor, and you do not plan to have one.
- You have not had a major infection (like serious pneumonia or bloodstream infection) in the last 3 months, and you do not have an active infection needing antibiotics or antivirals.
- Your spleen has not been removed, and you have not been diagnosed with bronchiectasis (a lung condition).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.